| Document |
Document Title |
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/016182A1 |
Ligand-drug conjugates for targeted melanoma therapies are disclosed herein. A ligand is conjugated to a cytotoxic cancer drug through a cleavage linker. The ligand can bind to an overexpressed receptor on a cancer cell, resulting in sel...
|
|
WO/2021/010482A1 |
The present invention provides a peptide that disrupts the self-aggregation of an AtaA polypeptide or separates a bond between the AtaA polypeptide and another subject. A peptide found by the present inventors has the properties of disru...
|
|
WO/2021/004463A1 |
A method for preparing an antioxidative peptide from a peanut meal by employing a high pressure-assisted enzymatic hydrolysis method, comprising the extraction of heat denatured protein in the peanut meal, high-pressure preprocessing, en...
|
|
WO/2021/003399A1 |
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the anti...
|
|
WO/2021/001244A1 |
The present invention relates to a compound for stabilizing enzymes, the use of said compound for stabilizing an enzyme, a composition comprising said compound, a method of preparing the composition comprising said compound, a detergent ...
|
|
WO/2021/003171A2 |
The present disclosure is directed to peptoids and peptoid multimers that inhibit IL-15 and their use in treating autoimmune/infiammatory diseases.
|
|
WO/2021/002408A1 |
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention is a method for manufacturing a fluoroalkyl-group-containing peptide in which a compound represented by general formula (6-2) or (...
|
|
WO/2020/264187A1 |
The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine...
|
|
WO/2020/259726A1 |
The present invention relates to cyclen based compounds of general formula (I), wherein X is nitrogen and Y, Z are –CH-, or X, Z are –CH- and Y is nitrogen, or X, Y are –CH- and Z is nitrogen; R1 is independently selected from H; C...
|
|
WO/2020/260309A1 |
The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further p...
|
|
WO/2020/257745A1 |
Compounds, compositions, and methods are provided that are useful in treating brain diseases by effecting delivery across the blood brain barrier of molecules that otherwise do not (or insignificantly) pass across the blood brain barrier...
|
|
WO/2020/249745A1 |
The present invention relates to cationic micelles, and in particular the compounds capable of forming such cationic micelles for use in cell tracking.
|
|
WO/2020/244224A1 |
Disclosed are a tripeptide propylene oxide derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The structure of the tripeptide ethylene oxide derivative is as represented by...
|
|
WO/2020/245772A1 |
The present invention relates to bioactive peptides and to the cosmeceutical compositions comprising them, useful for the prevention and treatment of the signs of skin aging, such as wrinkles, fine lines and loss of firmness and elastici...
|
|
WO/2020/237375A1 |
The disclosure pertains to conformational epitopes in oligomeric tau, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. The antibodies bind activity neutralizing sites in tau. Also provided ar...
|
|
WO/2020/235567A1 |
[Problem] To provide a novel fluorescent probe which can be used in a spray mode, has excellent specificity to sensitivity, also has immediacy, and enables the detection of brain tumor. [Solution] A fluorescent probe for use in the detec...
|
|
WO/2020/236146A1 |
Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids incl...
|
|
WO/2020/236808A1 |
This disclosure relates to processes for preparing compounds that are useful in the treatment of disease, such as cancer, in mammals. In particular, the invention described herein pertains to processes for preparing compounds capable of ...
|
|
WO/2020/230884A1 |
Provided is a cell culturing scaffold material having excellent adhesiveness for cells. This cell culturing scaffold material contains a peptide-including polyvinyl alcohol derivative that has a polyvinyl alcohol derivative part and a pe...
|
|
WO/2020/229693A1 |
This invention relates pharmaceutical compositions comprising a protein as the active ingredient together with one or more dipeptides as stabilising agents, and optionally an enzyme inhibitor. The compositions are particularly useful for...
|
|
WO/2020/228097A1 |
Provided are a cyclic peptide compound simulating a natural product structure, and a method for preparation thereof. The preparation method is: the compound of formula I, a divalent palladium catalyst, and a silver salt undergoing an int...
|
|
WO/2020/230886A1 |
Provided is a resin film formed of a scaffold material for cell culture, said resin film enabling excellent fixation of cells after seeding and thus contributing to an increase in the cell proliferation rate. The resin film is formed o...
|
|
WO/2020/230885A1 |
Provided is a cell culturing scaffolding material having excellent extensibility of a pseudopodium and an excellent cell-proliferation property. A cell culturing scaffolding material according to the present invention includes a peptid...
|
|
WO/2020/227134A1 |
A method for treating opioid use disorder comprises administering to a subject a pharmaceutical composition comprising a cyclic peptide of Formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier; ...
|
|
WO/2020/227376A1 |
The present invention generally relates to transplantation rejection. In particular, the present invention provides compositions, kits, assays, and methods of determining if a subject has allograft rejection, or an increased risk of deve...
|
|
WO/2020/227625A1 |
Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodi...
|
|
WO/2020/223403A1 |
Embodiments provide for compositions and methods concerning lipid modification of Smacs for use in treating cancer.
|
|
WO/2020/223581A1 |
A poly-N-substituted glycine compound of a formula A-(X-Y-Z)n-B is provided, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH2, one and two N-substituted glycine ...
|
|
WO/2020/223730A1 |
The present disclosure provides a supramolecular (self-assembling) polypeptide complex that comprises a plurality of randomized polyamino acids that self-assemble into nanofibers and methods of making and using same.
|
|
WO/2020/220023A1 |
The present disclosure relates to compounds according to Formula I. These compounds display very good binding affinities to the PSMA binding sites. They comprise a radioactive isotope or a chelating moiety that can be labeled with a radi...
|
|
WO/2020/215156A1 |
There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glyc...
|
|
WO/2020/218450A1 |
The present invention addresses the problem of providing a novel peptide which can treat, prevent or ameliorate anorexia. The present invention provides a peptide described in any one of the following items (1) to (3). (1) A peptide co...
|
|
WO/2020/216240A1 |
The present invention belongs to the field of medicine, and specifically discloses a compound of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in the preparation of a me...
|
|
WO/2020/215034A1 |
The present disclosure provides a method of preventing and/or treating hepatocellular apoptosis and liver damage in a liver disease, particularly NASH, by targeting the AMPK/caspase-6 axis to inhibit caspase-6 activity and/or activate AM...
|
|
WO/2020/210689A1 |
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, M and n are as defined herein. Methods a...
|
|
WO/2020/206000A1 |
The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs, e.g., compounds of Formula I (including Formulas IA, IB, IC, ID, IE, IF, and IG), a stereoi...
|
|
WO/2020/200880A1 |
A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an anti...
|
|
WO/2020/194058A1 |
The invention relates in various aspects to a salt form S-(N, N-diethylcarbamoyl)glutathione, a method of producing the salt form, a pharmaceutical composition comprising said salt form. The invention also relates to a method of preventi...
|
|
WO/2020/194304A1 |
A piezoelectric transducer is provided herein, comprising a three-dimensional structure made of a plurality of peptides, the peptides being self-assembling and the structure being piezoelectric, wherein at least a portion, or each, of sa...
|
|
WO/2020/193673A1 |
The present invention relates to a family of peptides which are able to increase synthesis of homeodomain protein Mohawk and, hence, are useful as anti-aging 5 agents and as rejuvenating agents.
|
|
WO/2020/187721A1 |
A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.
|
|
WO/2020/181687A1 |
A preparation method for and an intermediate of a drug-linker for an antibody drug conjugate MC-MMAF. The reaction activity of the N-terminus is improved, so that the occurrence of a racemic reaction is effectively controlled. The toxin ...
|
|
WO/2020/181688A1 |
The present invention sets forth a preparation method for a drug-linker MC-MMAF used as an antibody-drug conjugate, and an intermediate thereof. The preparation method of the present invention improves the reactivity of an N-terminal, th...
|
|
WO/2020/178841A1 |
Self-assembled structures formed of a plurality of cyclic peptides which are in association with metal ions is provided. The cyclic peptides are each of from 2 to 6 amino acid residues, and two or more of the amino acid residues are each...
|
|
WO/2020/172749A1 |
Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as metho...
|
|
WO/2020/175570A1 |
A brain function regulator that comprises a peptide containing an amino acid sequence represented by Glu-Hyp-Gly, a salt thereof or a chemical modification of the same.
|
|
WO/2020/172072A1 |
This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for treating various diseases or disorders (e.g., IgE-mediated disorders). The methods include administering to the subject an effective amount of a c...
|
|
WO/2020/172197A1 |
The present disclosure provides labeling reagents for labeling substrates such as nucleotides, proteins, antibodies, lipids, and cells. The labeling reagents provided herein may comprise fluorescent labels and semi-rigid linkers. Methods...
|
|
WO/2020/170185A1 |
The present invention provides substantially pure Lanreotide or its salt and preparation thereof. In another aspect present invention provides a method of preparing Lanreotide dmg product which involves measuring D-Allo-Threonine Lanreot...
|
